The availability of our team to support you has not changed as a result of COVID-19. If there is a way we can assist you, we are here to help - Contact us

Custom engineering service

Flexible engineering to match your requirements

Working with you - from target identification to pre-clinical studies

Confirm your target - Understand the effects of disease mutations - Evaluate your therapeutics

 

From consultation to delivery

Discuss your requirements with our experienced cell line engineering team.

We can support a range of edit and cell types, including:

Deletions Reporters and tags
Large coding knock ins Conditional knockout and knock ins
Multiplex editing Expression by lentivirus
Scarless editing Inducible and constitutive models
Safe harbor or random integration of expression cassette iPSC and primary t cell editing

 

Work with your cell line of choice

Provide your in-house cell line, incorporated at no extra cost, or choose from hundreds of pre-licensed cell lines

As soon as your project plan is agreed, work starts

  • Facilitated by in-house automation
  • Flexible capacity to minimize project delays  

Start your project

  1. Build your cell line using our online form to send us your requirements
  2. You will automatically receive a quote via email
  3. Your project undergoes an in-depth technical review
  4. Project plan is agreed and work starts

Build your cell line

 

Support from dedicated project management

  • On-boarding of your cell line
  • Monthly updates on project progress
  • Final reporting
  • Transition to your next steps

Everything you need, confidently delivered

You will receive 2 clonal cell models to avoid clonal bias, as well as the parental cell line for a wildtype control.

As standard, we provide a final project report, which includes:

  • Sequencing confirmation
  • Mycoplasma and sterility testing
  • IP and license package as required

 

Discuss your cell line engineering requirements with our expert team 

Contact us

Note: Certain drug screening, target validation and toxicity testing methods that utilize in-vitro differentiated cells that are induced to display a disease phenotype, may be covered by one or more patents controlled by Axiogenesis and Evotec. Those patents include EP2270196B1, EP1745144B1 and EP3070174B1 and corresponding foreign patents and pending applications. The purchase or transfer of this product is not intended, either expressly or by implication, to grant any right or license to practice under the foregoing patents. Purchasers are advised to contact Evotec for information regarding a license to practice under such patents.